Dose Escalation Study to Assess the Pharmacokinetic Parameters of a Nano-amorphous Oral Sirolimus Formulation in Healthy Volunteers-Reference-Cited by-同舟云学术

Dose Escalation Study to Assess the Pharmacokinetic Parameters of a Nano-amorphous Oral Sirolimus Formulation in Healthy Volunteers

Published:2019-05-14 Issue:6 Volume:44 Page:777-785
ISSN:0378-7966
Container-title:European Journal of Drug Metabolism and Pharmacokinetics
language:en
Short-container-title:Eur J Drug Metab Pharmacokinet

Author:

Basa-Dénes Orsolya,Angi Réka,Kárpáti Balázs,Jordán Tamás,Ötvös Zsolt,Erdősi Nikoletta,Ujhelyi Andrea,Ordasi Betti,Molnár László,McDermott John,Roe Chris,McKenzie Litza,Solymosi Tamás,Heltovics Gábor,Glavinas Hristos^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s13318-019-00562-y.pdf

Reference20 articles.

1. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 2003;35:7S–14S.

2. Napoli KL, Taylor PJ. From beach to bedside: history of the development of sirolimus. Ther Drug Monit. 2001;23:559–86.

3. Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov. 2011;10:868–80. https://doi.org/10.1038/nrd3531 .

4. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol. 2005;16:525–37. https://doi.org/10.1093/annonc/mdi113 .

5. Law BK. Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol. 2005;56:47–60. https://doi.org/10.1016/j.critrevonc.2004.09.009 .

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preventative treatment of tuberous sclerosis complex with sirolimus: Phase I safety and efficacy results;Annals of the Child Neurology Society;2024-04-22

2. Bio-enabling strategies to mitigate the pharmaceutical food effect: A mini review;International Journal of Pharmaceutics;2022-05

3. Novel multifunctional NIR-II aggregation-induced emission nanoparticles-assisted intraoperative identification and elimination of residual tumor;Journal of Nanobiotechnology;2022-03-19

4. Ion Channel Drugs Suppress Cancer Phenotype in NG108-15 and U87 Cells: Toward Novel Electroceuticals for Glioblastoma;Cancers;2022-03-15